Similis Bio And Blau Farmaceutica Enter Into Development And License Agreement For Biosimilars - Life Sciences, Biotechnology & Nanotechnology
On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences's business unit focused on biosimilar development, has signed its first development and license agreement...
Source: mondaq.com